The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Stopped Due to difficulties with enrollment, the study was terminated early.
Conditions
- Opioid-Induced Constipation
Interventions
- DRUG: CB-5945
- DRUG: Placebo
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)